PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios

Achilles Therapeutics plc (ACHL)

Equity · Currency in USD · Last updated Sep 28, 2023
SummaryFinancials

Company Info

ISINUS00449L1026
CUSIP00449L102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$38.90M
EPS-$1.89
EBITDA (TTM)-$64.23M
Year Range$0.75 - $2.52
Target Price$8.80
Short %3.59%
Short Ratio0.41

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Achilles Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%AprilMayJuneJulyAugustSeptember
0.36%
5.15%
ACHL (Achilles Therapeutics plc)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACHL

Achilles Therapeutics plc

Return

Achilles Therapeutics plc had a return of 2.60% year-to-date (YTD) and -65.74% in the last 12 months.


PeriodReturnBenchmark
1 month3.75%-3.58%
6 months1.91%5.75%
Year-To-Date2.60%10.93%
1 year-65.74%16.78%
5 years (annualized)-68.77%2.96%
10 years (annualized)N/AN/A

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-11.29%-12.95%-13.32%20.48%-5.48%7.91%-8.80%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Achilles Therapeutics plc (ACHL) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ACHL
Achilles Therapeutics plc
-1.05
^GSPC
S&P 500
0.98

Sharpe Ratio

The current Achilles Therapeutics plc Sharpe ratio is -1.05. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00AprilMayJuneJulyAugustSeptember
-1.05
0.88
ACHL (Achilles Therapeutics plc)
Benchmark (^GSPC)

Dividend History


Achilles Therapeutics plc doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AprilMayJuneJulyAugustSeptember
-94.83%
-11.20%
ACHL (Achilles Therapeutics plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Achilles Therapeutics plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Achilles Therapeutics plc is 95.58%, recorded on Dec 21, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.58%Apr 7, 2021432Dec 21, 2022
-9.85%Apr 1, 20212Apr 5, 20211Apr 6, 20213

Volatility Chart

The current Achilles Therapeutics plc volatility is 16.17%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%AprilMayJuneJulyAugustSeptember
16.17%
3.12%
ACHL (Achilles Therapeutics plc)
Benchmark (^GSPC)